MedPath

Mesalamine

MESALAMINE SUPPOSITORIES

Approved
Approval ID

aa63b4bb-2de7-40aa-b26b-1b00b0183eac

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 31, 2022

Manufacturers
FDA

Zydus Lifesciences Limited

DUNS: 918596198

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Mesalamine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70771-1513
Application NumberANDA208953
Product Classification
M
Marketing Category
C73584
G
Generic Name
Mesalamine
Product Specifications
Route of AdministrationRECTAL
Effective DateOctober 31, 2022
FDA Product Classification

INGREDIENTS (2)

FAT, HARDInactive
Code: 8334LX7S21
Classification: IACT
MESALAMINEActive
Quantity: 1000 mg in 1 1
Code: 4Q81I59GXC
Classification: ACTIB

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 2/13/2020

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70771-1513-6

Mesalamine suppositories, 1000 mg

30 rectal suppositories

Rx only

Blister label

Image

NDC 70771-1513-7

Mesalamine rectal suppositories, 1000 mg

30 rectal suppositories

Rx only

Carton label

Image

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 9/4/2020

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Mesalamine - FDA Drug Approval Details